貝泰妮(300957.SZ):擬聘請羅兵鹹永道為公司H股發行並上市審計機構
格隆匯7月22日丨貝泰妮(300957.SZ)公佈,公司於2021年7月22日召開了第一屆董事會第十七次會議及第一屆監事會第十次會議,分別審議通過了《關於聘請H股發行並上市審計機構的議案》,同意聘請羅兵鹹永道會計師事務所(“羅兵鹹永道”)為公司H股發行並上市審計機構。
鑑於公司已啟動發行境外上市外資股(H股)並申請在香港聯合交易所有限公司主板掛牌上市事宜,考慮到羅兵鹹永道在H股發行並上市項目方面擁有較為豐富的財務審計經驗,經過綜合考量和審慎評估,公司董事會決定聘請羅兵鹹永道為本次發行上市審計機構。該事項尚需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.